BioNTech (NASDAQ:BNTX) Price Target Cut to $122.00 by Analysts at JPMorgan Chase & Co.

BioNTech (NASDAQ:BNTX) had its price target cut by JPMorgan Chase & Co. from $124.00 to $122.00 in a research report released on Tuesday,Benzinga reports. They currently have a neutral rating on the stock.

A number of other equities analysts have also recently issued reports on the company. Hsbc Global Res upgraded BioNTech from a “hold” rating to a “strong-buy” rating in a report on Friday, August 2nd. UBS Group increased their price target on shares of BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a research report on Wednesday, September 18th. Jefferies Financial Group upgraded shares of BioNTech from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $96.00 to $150.00 in a report on Tuesday, September 17th. Evercore ISI raised shares of BioNTech from an “in-line” rating to an “outperform” rating and upped their price objective for the company from $110.00 to $125.00 in a research note on Tuesday, November 19th. Finally, The Goldman Sachs Group upgraded shares of BioNTech from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $90.00 to $137.00 in a research report on Friday, November 8th. Four research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, BioNTech currently has an average rating of “Moderate Buy” and an average price target of $138.67.

BioNTech Trading Up 1.8 %

Shares of BioNTech stock opened at $120.72 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. BioNTech has a 1 year low of $76.53 and a 1 year high of $131.49. The firm has a market cap of $28.94 billion, a PE ratio of -57.49 and a beta of 0.26. The company has a 50 day simple moving average of $113.52 and a two-hundred day simple moving average of $98.35.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.26) by $2.07. The company had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm’s revenue was up 38.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.73 EPS. Analysts expect that BioNTech will post -3.68 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioNTech

Several hedge funds have recently made changes to their positions in the business. Candriam S.C.A. boosted its holdings in BioNTech by 261.2% in the second quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock valued at $46,526,000 after acquiring an additional 418,695 shares in the last quarter. Baillie Gifford & Co. lifted its position in shares of BioNTech by 0.4% in the 3rd quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock worth $986,750,000 after purchasing an additional 31,773 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in shares of BioNTech by 63.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 18,939 shares of the company’s stock valued at $2,249,000 after purchasing an additional 7,340 shares in the last quarter. Discovery Capital Management LLC CT purchased a new position in shares of BioNTech during the second quarter valued at about $2,467,000. Finally, Deerfield Management Company L.P. Series C raised its stake in BioNTech by 4.3% in the second quarter. Deerfield Management Company L.P. Series C now owns 594,000 shares of the company’s stock worth $47,734,000 after buying an additional 24,426 shares in the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.